GE HealthCare Trial Seeks Manganese MRI Edge With Valuation Upside

GE HealthCare Technologies (NasdaqGS:GEHC) has dosed the first patient in its global LUMINA Phase 2/3 trial of mangaciclanol, ...
Zacks Investment Research on MSN

GEHC moves manganese-based MRI contrast agent into phase 2/3 trial

GE HealthCare Technologies Inc. GEHC recently announced that the first patient has been dosed in its Phase 2/3 LUMINA ...

First patient dosed in GE HealthCare’s Phase II/III LUMINA clinical trial

Mangaciclanol’s Phase I trial showed it was well tolerated, with no serious adverse events or clinically significant findings ...

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation ...

GE HealthCare announces first patient dosed in Phase 2/3 LUMINA trial for manganese-based MRI contrast agent under FDA Fast Track designation ...
Seeking Alpha

Sanochemia/SPL: Investigational Iron-Based MRI Contrast Agent Meets Primary Endpoints in Pivotal Phase III Study

NEUFELD, Austria, Feb. 25, 2025 /PRNewswire/ -- Sanochemia Pharmazeutika today announced positive headline results of the pivotal phase III study PROSTAPROGRESS on Ferumoxtran (EudraCT 2018-004310-18) ...
Pharmabiz

GE HealthCare doses first patient in phase 2/3 LUMINA trial for manganese-based MRI contrast agent, mangaciclanol

GE HealthCare doses first patient in phase 2/3 LUMINA trial for manganese-based MRI contrast agent, mangaciclanol: Chalfont St Giles,?UK Saturday, April 25, 2026, 12:00 Hrs [IST] ...
The American Journal of Managed Care

Contrast Agent May Be Unnecessary in MRIs Checking Pediatric Growth

A review of cases using MRI with and without contrast agent found perfect or near-perfect agreement in most cases when evaluating patients with short stature for growth hormone deficiency. Gadolinium ...
Medscape

Gadofullerene MRI Contrast Agents

With their special metal-ion chelation unlike that offered by any classic coordination complex, high water-proton relaxivities and their flexible surface functionalization chemistry, gadofullerenes ...
Case Western Reserve University

MRI contrast agent locates and distinguishes aggressive from slow-growing breast cancer

A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between ...
UPI

Cardiac MRI contrast agents unlikely to produce adverse reactions, study finds

Oct. 29 (UPI) --Chemicals used to improve images of the heart during MRI scans are unlikely to produce allergic reactions and other side effects in patients who take them, according to a study ...
Business Wire

Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies

BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...
Science Daily

Analysis of MRI contrast agents

Simulations reveal details about the magnetic interactions between gadolinium contrast agents used in MRI scans and their environment. You can keep your best guesses. Engineers at Rice University's ...